Clinical effects of lianbai liquid in prevention and treatment of dermal injury caused by radiotherapy.
To observe the effect of Lianbai liquid in prevention and treatment of acute radiation dermal injury. From May 2000 to December 2005, 126 cancer patients were randomly divided into a prevention group of 75 cases given externally topical application of Lianbai liquid since the first radiotherapy, and a control group I of 51 cases given only advice after radiotherapy; while the other 92 cancer patients who had already had grade III acute radiation-induced dermal injury were randomly divided into a treatment group of 54 cases treated by externally topical use of Lianbai liquid, and a control group II of 38 cases treated by topical use of norfloxacin. Clinical evaluation was carried out according to the CTC.V2.0 standard stipulated by NCI for classifying acute radiation dermal injury. The incidence of skin reaction was 32.0% in the prevention group and 92.2% in the control group I, with an obvious difference between the two groups (chi2=54.163, P<0.01). Mild radioactive reaction (grade I and II) was 28.0% (21/75) in the prevention group and 70.6% (36/51) in the control group I, with a remarkable difference between the two groups (chi2=22.226, P<0.01). The effective rate for grade III dermal injury was 92.6% (50/54) in the treatment group and 65.9% (25/38) in the control group II, with a remarkable difference between the two groups (chi2=6.018, P=0.024). The wound-healing time was 11.07+/-2.21 days in the treatment group and 18.08+/-1.76 days in the control group II, with a remarkable difference between the two groups (u=16.932, P<0.01). Lianbai liquid can effectively prevent the radiation dermatitis, and treat grade III acute radiation dermal injury with obvious curative effect.